Symbols / INM $0.69 +2.46% InMed Pharmaceuticals Inc.
INM Chart
About
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with unmet medical needs. The company's lead product consists of INM-755, a cannabinol topical skin cream that has completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, a small molecule compound that acts as a selective dual CB1/CB2 agonist; and INM-900 for neurodegenerative diseases, as well as INM-901, a small molecule for treatment of Alzheimer's disease. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Drug Manufacturers - Spe | Market Cap | 2.03M |
| Enterprise Value | -4.49M | Income | -7.66M | Sales | 4.51M |
| Book/sh | 3.42 | Cash/sh | 2.40 | Dividend Yield | — |
| Payout | 0.00% | Employees | 13 | IPO | — |
| P/E | — | Forward P/E | -0.11 | PEG | — |
| P/S | 0.45 | P/B | 0.20 | P/C | — |
| EV/EBITDA | 0.59 | EV/Sales | -1.00 | Quick Ratio | 4.85 |
| Current Ratio | 5.94 | Debt/Eq | 5.55 | LT Debt/Eq | — |
| EPS (ttm) | -2.88 | EPS next Y | -6.25 | EPS Growth | — |
| Revenue Growth | -26.20% | Earnings | 2026-05-12 | ROA | -49.77% |
| ROE | -97.20% | ROIC | — | Gross Margin | 29.73% |
| Oper. Margin | -258.57% | Profit Margin | -170.07% | Shs Outstand | 2.92M |
| Shs Float | 2.09M | Short Float | 2.30% | Short Ratio | 0.87 |
| Short Interest | — | 52W High | 7.98 | 52W Low | 0.57 |
| Beta | 0.52 | Avg Volume | 120.28K | Volume | 22.14K |
| Target Price | — | Recom | None | Prev Close | $0.68 |
| Price | $0.69 | Change | 2.46% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
News
RSS: Latest INM news- InMed (NASDAQ: INM) files ATM prospectus supplement under S-3 shelf - Stock Titan Fri, 03 Apr 2026 20
- 2026 Kevin O’Leary Complete Stock Portfolio List & Top 10 Dividend Picks Now - Sure Dividend Wed, 18 Mar 2026 07
- InMed outlines 2026 development plans for lead programs - tipranks.com Mon, 09 Mar 2026 07
- Can InMed Pharmaceuticals Stock Recover If Markets Fall? - Trefis Sun, 14 Dec 2025 08
- INM 8-K & SEC Filings - Yahoo Finance Australia Fri, 03 Apr 2026 12
- IBM is the latest AI casualty. Shares tank 13% on Anthropic programming language threat - cnbc.com Mon, 23 Feb 2026 08
- InMed has 180 days to lift its stock above $1 and stay on Nasdaq - Stock Titan Fri, 27 Mar 2026 07
- Wall Street's First Blockbuster Stock Split Announcement of 2026 Is Here -- and This Industry Leader Has Skyrocketed Over 27,000% in 25 Years - The Motley Fool hu, 19 Feb 2026 08
- 3 Best Stocks To Buy And Invest Now For March 2026 - Forbes Fri, 20 Feb 2026 08
- INM Pharma Stock’s Sudden Leap: What’s Next? - StocksToTrade Mon, 02 Jun 2025 07
- InMed warned by Nasdaq over minimum bid price non-compliance - tipranks.com Fri, 27 Mar 2026 07
- Lab-grown human brain tissue backs InMed’s Alzheimer’s drug ahead of trials - Stock Titan Mon, 23 Mar 2026 07
- U.S. law threat pushes InMed to shut BayMedica unit, pivot to Alzheimer's drugs - Stock Titan Fri, 06 Mar 2026 08
- InMed Highlights Q2 Results Amid Cash, Regulatory Pressures - tipranks.com hu, 12 Feb 2026 08
- [EFFECT] InMed Pharmaceuticals Inc. SEC Filing - Stock Titan ue, 31 Mar 2026 04
Financials
| Line Item | Trend | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Total Revenue |
|
4.94
+7.50%
|
4.60
+11.18%
|
4.14
+279.61%
|
1.09
|
| Operating Revenue |
|
4.94
+7.50%
|
4.60
+11.18%
|
4.14
+279.61%
|
1.09
|
| Cost Of Revenue |
|
3.24
-7.46%
|
3.50
+27.97%
|
2.73
+400.56%
|
0.55
|
| Reconciled Cost Of Revenue |
|
2.91
-6.35%
|
3.11
+33.06%
|
2.34
+964.25%
|
0.22
|
| Gross Profit |
|
1.71
+55.02%
|
1.10
-21.53%
|
1.40
+158.13%
|
0.54
|
| Operating Expense |
|
9.62
+4.21%
|
9.24
-5.59%
|
9.78
-31.76%
|
14.34
|
| Research And Development |
|
2.85
-11.30%
|
3.22
-13.79%
|
3.73
-48.75%
|
7.28
|
| Selling General And Administration |
|
6.56
+13.10%
|
5.80
-0.84%
|
5.85
-14.85%
|
6.87
|
| General And Administrative Expense |
|
6.56
+13.10%
|
5.80
-0.84%
|
5.85
-14.85%
|
6.87
|
| Other Gand A |
|
6.56
+13.10%
|
5.80
-0.84%
|
5.85
-14.85%
|
6.87
|
| Total Expenses |
|
12.86
+1.01%
|
12.73
+1.74%
|
12.51
-15.90%
|
14.88
|
| Operating Income |
|
-7.92
+2.66%
|
-8.13
+2.92%
|
-8.38
+39.25%
|
-13.79
|
| EBITDA |
|
-7.26
-2.72%
|
-7.06
+9.24%
|
-7.78
+41.39%
|
-13.28
|
| Normalized EBITDA |
|
-7.23
-3.22%
|
-7.00
+9.47%
|
-7.73
+7.65%
|
-8.38
|
| Reconciled Depreciation |
|
0.53
-11.55%
|
0.60
+1.43%
|
0.60
+16.45%
|
0.51
|
| EBIT |
|
-7.79
-1.59%
|
-7.67
+8.48%
|
-8.38
+39.25%
|
-13.79
|
| Total Unusual Items |
|
-0.03
+54.02%
|
-0.06
-28.53%
|
-0.05
+99.02%
|
-4.90
|
| Total Unusual Items Excluding Goodwill |
|
-0.03
+54.02%
|
-0.06
-28.53%
|
-0.05
+99.02%
|
-4.90
|
| Special Income Charges |
|
—
|
—
|
0.00
+100.00%
|
-3.47
|
| Impairment Of Capital Assets |
|
—
|
—
|
0.00
-100.00%
|
3.47
|
| Net Income |
|
-8.16
-6.34%
|
-7.68
+3.42%
|
-7.95
+57.27%
|
-18.60
|
| Pretax Income |
|
-8.16
-6.44%
|
-7.67
+3.35%
|
-7.93
+57.34%
|
-18.60
|
| Net Non Operating Interest Income Expense |
|
-0.22
-140.85%
|
0.53
+7.20%
|
0.49
+412.48%
|
0.10
|
| Interest Expense Non Operating |
|
0.37
|
0.00
|
—
|
0.00
|
| Net Interest Income |
|
-0.22
-140.85%
|
0.53
+7.20%
|
0.49
+412.48%
|
0.10
|
| Interest Expense |
|
0.37
|
0.00
|
—
|
0.00
|
| Interest Income Non Operating |
|
0.16
-70.47%
|
0.53
+7.20%
|
0.49
+412.48%
|
0.10
|
| Interest Income |
|
0.16
-70.47%
|
0.53
+7.20%
|
0.49
+412.48%
|
0.10
|
| Other Income Expense |
|
-0.03
+54.02%
|
-0.06
-28.53%
|
-0.05
+99.02%
|
-4.90
|
| Gain On Sale Of Security |
|
-0.03
+54.02%
|
-0.06
-28.53%
|
-0.05
+96.64%
|
-1.43
|
| Tax Provision |
|
0.00
-100.00%
|
0.01
-45.80%
|
0.01
|
0.00
|
| Tax Rate For Calcs |
|
0.00
-100.00%
|
0.00
-62.50%
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
+100.00%
|
-0.01
+51.80%
|
-0.02
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-8.16
-6.34%
|
-7.68
+3.42%
|
-7.95
+57.27%
|
-18.60
|
| Net Income From Continuing Operation Net Minority Interest |
|
-8.16
-6.34%
|
-7.68
+3.42%
|
-7.95
+57.27%
|
-18.60
|
| Net Income From Continuing And Discontinued Operation |
|
-8.16
-6.34%
|
-7.68
+3.42%
|
-7.95
+57.27%
|
-18.60
|
| Net Income Continuous Operations |
|
-8.16
-6.34%
|
-7.68
+3.42%
|
-7.95
+57.27%
|
-18.60
|
| Normalized Income |
|
-8.13
-6.70%
|
-7.62
+3.74%
|
-7.92
+42.18%
|
-13.70
|
| Net Income Common Stockholders |
|
-8.16
-6.34%
|
-7.68
+3.42%
|
-7.95
+57.27%
|
-18.60
|
| Diluted EPS |
|
-8.36
+58.61%
|
-20.20
+68.92%
|
-65.00
+90.20%
|
-663.40
|
| Basic EPS |
|
-8.36
+58.61%
|
-20.20
+68.92%
|
-65.00
+90.20%
|
-663.40
|
| Basic Average Shares |
|
0.98
+156.13%
|
0.38
+211.26%
|
0.12
+336.58%
|
0.03
|
| Diluted Average Shares |
|
0.98
+156.13%
|
0.38
+211.26%
|
0.12
+336.58%
|
0.03
|
| Diluted NI Availto Com Stockholders |
|
-8.16
-6.34%
|
-7.68
+3.42%
|
-7.95
+57.27%
|
-18.60
|
| Depreciation Amortization Depletion Income Statement |
|
0.21
-3.08%
|
0.22
+8.58%
|
0.20
+8.94%
|
0.19
|
| Depreciation And Amortization In Income Statement |
|
0.21
-3.08%
|
0.22
+8.58%
|
0.20
+8.94%
|
0.19
|
| Line Item | Trend | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Total Assets |
|
15.58
+31.78%
|
11.82
-16.19%
|
14.11
+10.31%
|
12.79
|
| Current Assets |
|
12.87
+48.08%
|
8.69
-23.32%
|
11.33
+18.07%
|
9.60
|
| Cash Cash Equivalents And Short Term Investments |
|
11.08
+68.54%
|
6.57
-26.27%
|
8.91
+44.29%
|
6.18
|
| Cash And Cash Equivalents |
|
11.08
+68.54%
|
6.57
-26.27%
|
8.91
+44.29%
|
6.18
|
| Other Short Term Investments |
|
—
|
—
|
—
|
0.04
|
| Receivables |
|
0.47
+31.82%
|
0.35
+35.50%
|
0.26
+195.82%
|
0.09
|
| Accounts Receivable |
|
0.47
+31.82%
|
0.35
+35.50%
|
0.26
+195.82%
|
0.09
|
| Gross Accounts Receivable |
|
0.47
+32.51%
|
0.35
+7.84%
|
0.33
|
—
|
| Allowance For Doubtful Accounts Receivable |
|
-0.00
|
0.00
+100.00%
|
-0.07
|
—
|
| Inventory |
|
0.96
-22.76%
|
1.24
-23.02%
|
1.62
-35.11%
|
2.49
|
| Raw Materials |
|
0.26
-30.69%
|
0.37
+78.55%
|
0.21
-28.66%
|
0.29
|
| Work In Process |
|
0.03
-13.38%
|
0.03
-94.01%
|
0.51
-70.19%
|
1.72
|
| Finished Goods |
|
0.68
-19.58%
|
0.84
-5.90%
|
0.89
+88.73%
|
0.47
|
| Prepaid Assets |
|
—
|
—
|
—
|
0.80
|
| Restricted Cash |
|
0.04
+0.74%
|
0.04
-3.06%
|
0.04
-0.85%
|
0.04
|
| Other Current Assets |
|
0.32
-32.65%
|
0.48
-4.07%
|
0.50
-37.53%
|
0.80
|
| Total Non Current Assets |
|
2.71
-13.42%
|
3.13
+12.92%
|
2.77
-13.02%
|
3.19
|
| Net PPE |
|
0.99
-20.62%
|
1.25
+72.79%
|
0.72
-20.00%
|
0.90
|
| Gross PPE |
|
2.33
-10.55%
|
2.61
+58.02%
|
1.65
+16.05%
|
1.42
|
| Accumulated Depreciation |
|
-1.34
+1.25%
|
-1.36
-46.47%
|
-0.93
-79.16%
|
-0.52
|
| Properties |
|
—
|
—
|
—
|
0.00
|
| Machinery Furniture Equipment |
|
0.00
-100.00%
|
0.04
+0.00%
|
0.04
+0.00%
|
0.04
|
| Other Properties |
|
2.33
-9.14%
|
2.56
+59.48%
|
1.61
+16.52%
|
1.38
|
| Leases |
|
—
|
—
|
—
|
0.04
|
| Goodwill And Other Intangible Assets |
|
1.62
-9.12%
|
1.78
-8.38%
|
1.95
-7.71%
|
2.11
|
| Other Intangible Assets |
|
1.62
-9.12%
|
1.78
-8.38%
|
1.95
-7.71%
|
2.11
|
| Other Non Current Assets |
|
0.10
+0.00%
|
0.10
-4.68%
|
0.10
-40.61%
|
0.18
|
| Total Liabilities Net Minority Interest |
|
2.15
-18.00%
|
2.62
+29.76%
|
2.02
-45.63%
|
3.71
|
| Current Liabilities |
|
1.84
-6.70%
|
1.97
-1.44%
|
2.00
-39.73%
|
3.32
|
| Payables And Accrued Expenses |
|
0.91
-21.60%
|
1.17
+9.31%
|
1.07
-61.59%
|
2.78
|
| Payables |
|
0.37
-40.89%
|
0.63
+15.07%
|
0.54
-67.34%
|
1.67
|
| Accounts Payable |
|
0.37
-40.89%
|
0.63
+15.07%
|
0.54
-53.33%
|
1.17
|
| Other Payable |
|
—
|
—
|
—
|
0.50
|
| Current Accrued Expenses |
|
0.54
+0.78%
|
0.54
+3.31%
|
0.52
-52.95%
|
1.11
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
0.49
+0.44%
|
0.49
-9.96%
|
0.54
+289.81%
|
0.14
|
| Current Debt And Capital Lease Obligation |
|
0.44
+37.04%
|
0.32
-15.41%
|
0.38
-7.07%
|
0.40
|
| Current Capital Lease Obligation |
|
0.44
+37.04%
|
0.32
-15.41%
|
0.38
-7.07%
|
0.40
|
| Current Deferred Liabilities |
|
—
|
0.00
-100.00%
|
0.02
|
0.00
|
| Total Non Current Liabilities Net Minority Interest |
|
0.31
-52.59%
|
0.64
+3931.92%
|
0.02
-95.89%
|
0.39
|
| Long Term Debt And Capital Lease Obligation |
|
0.31
-52.59%
|
0.64
+3931.92%
|
0.02
-95.89%
|
0.39
|
| Long Term Capital Lease Obligation |
|
0.31
-52.59%
|
0.64
+3931.92%
|
0.02
-95.89%
|
0.39
|
| Stockholders Equity |
|
13.43
+45.93%
|
9.21
-23.85%
|
12.09
+33.17%
|
9.08
|
| Common Stock Equity |
|
13.43
+45.93%
|
9.21
-23.85%
|
12.09
+33.17%
|
9.08
|
| Capital Stock |
|
91.22
+10.19%
|
82.78
+6.65%
|
77.62
+9.76%
|
70.72
|
| Common Stock |
|
91.22
+10.19%
|
82.78
+6.65%
|
77.62
+9.76%
|
70.72
|
| Share Issued |
|
2.00
+348.97%
|
0.45
+167.98%
|
0.17
+411.51%
|
0.03
|
| Ordinary Shares Number |
|
2.00
+348.97%
|
0.45
+167.98%
|
0.17
+411.51%
|
0.03
|
| Additional Paid In Capital |
|
39.32
+11.18%
|
35.37
-1.04%
|
35.74
+12.80%
|
31.68
|
| Retained Earnings |
|
-117.24
-7.48%
|
-109.08
-7.57%
|
-101.40
-8.50%
|
-93.45
|
| Gains Losses Not Affecting Retained Earnings |
|
0.13
+0.00%
|
0.13
+0.00%
|
0.13
+0.00%
|
0.13
|
| Other Equity Adjustments |
|
0.13
+0.00%
|
0.13
+0.00%
|
0.13
+0.00%
|
0.13
|
| Total Equity Gross Minority Interest |
|
13.43
+45.93%
|
9.21
-23.85%
|
12.09
+33.17%
|
9.08
|
| Total Capitalization |
|
13.43
+45.93%
|
9.21
-23.85%
|
12.09
+33.17%
|
9.08
|
| Working Capital |
|
11.03
+64.15%
|
6.72
-28.01%
|
9.33
+48.63%
|
6.28
|
| Invested Capital |
|
13.43
+45.93%
|
9.21
-23.85%
|
12.09
+33.17%
|
9.08
|
| Total Debt |
|
0.74
-23.00%
|
0.96
+145.76%
|
0.39
-50.65%
|
0.79
|
| Capital Lease Obligations |
|
0.74
-23.00%
|
0.96
+145.76%
|
0.39
-50.65%
|
0.79
|
| Net Tangible Assets |
|
11.81
+59.15%
|
7.42
-26.82%
|
10.14
+45.54%
|
6.97
|
| Tangible Book Value |
|
11.81
+59.15%
|
7.42
-26.82%
|
10.14
+45.54%
|
6.97
|
| Foreign Currency Translation Adjustments |
|
—
|
—
|
—
|
0.13
|
| Line Item | Trend | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-7.77
-11.18%
|
-6.99
+4.08%
|
-7.28
+53.26%
|
-15.58
|
| Cash Flow From Continuing Operating Activities |
|
-7.77
-11.18%
|
-6.99
+4.08%
|
-7.28
+53.26%
|
-15.58
|
| Net Income From Continuing Operations |
|
-8.16
-6.34%
|
-7.68
+3.42%
|
-7.95
+57.27%
|
-18.60
|
| Depreciation Amortization Depletion |
|
0.53
-11.55%
|
0.60
+1.43%
|
0.60
+16.45%
|
0.51
|
| Depreciation |
|
0.37
-14.00%
|
0.43
+9.88%
|
0.39
+11.68%
|
0.35
|
| Amortization Cash Flow |
|
0.16
-5.37%
|
0.17
-15.03%
|
0.20
+27.02%
|
0.16
|
| Depreciation And Amortization |
|
0.53
-11.55%
|
0.60
+1.43%
|
0.60
+16.45%
|
0.51
|
| Amortization Of Intangibles |
|
0.16
-5.37%
|
0.17
-15.03%
|
0.20
+27.02%
|
0.16
|
| Other Non Cash Items |
|
-0.00
+97.20%
|
-0.00
-55.67%
|
-0.00
-100.06%
|
1.39
|
| Stock Based Compensation |
|
0.12
-13.37%
|
0.14
-50.49%
|
0.28
-60.14%
|
0.70
|
| Provisionand Write Offof Assets |
|
0.00
|
0.00
-100.00%
|
0.05
|
0.00
|
| Asset Impairment Charge |
|
0.00
-100.00%
|
0.31
-1.01%
|
0.31
-91.10%
|
3.47
|
| Operating Gains Losses |
|
0.08
+519.21%
|
0.01
+936.52%
|
0.00
-90.99%
|
0.01
|
| Gain Loss On Investment Securities |
|
—
|
—
|
—
|
—
|
| Net Foreign Currency Exchange Gain Loss |
|
0.08
+519.21%
|
0.01
+936.52%
|
0.00
-33.16%
|
0.00
|
| Change In Working Capital |
|
-0.34
+8.71%
|
-0.37
+34.73%
|
-0.57
+81.59%
|
-3.07
|
| Change In Receivables |
|
-0.11
-24.07%
|
-0.09
+57.82%
|
-0.22
-447.76%
|
-0.04
|
| Changes In Account Receivables |
|
-0.11
-24.07%
|
-0.09
+57.82%
|
-0.22
-447.76%
|
-0.04
|
| Change In Inventory |
|
0.28
+327.59%
|
0.07
-88.29%
|
0.57
+128.23%
|
-2.00
|
| Change In Prepaid Assets |
|
0.17
+757.72%
|
0.02
-93.22%
|
0.30
+56.92%
|
0.19
|
| Change In Payables And Accrued Expense |
|
-0.25
-651.50%
|
0.05
+105.61%
|
-0.81
+0.62%
|
-0.81
|
| Change In Other Working Capital |
|
—
|
-0.02
-200.00%
|
0.02
+414.49%
|
-0.01
|
| Change In Other Current Assets |
|
0.00
-100.00%
|
0.00
-10.88%
|
0.01
+108.96%
|
-0.06
|
| Change In Other Current Liabilities |
|
-0.43
-8.17%
|
-0.40
+6.83%
|
-0.43
-24.78%
|
-0.34
|
| Investing Cash Flow |
|
0.00
+100.00%
|
-0.01
+98.60%
|
-0.66
+1.66%
|
-0.67
|
| Cash Flow From Continuing Investing Activities |
|
0.00
+100.00%
|
-0.01
+98.60%
|
-0.66
+1.66%
|
-0.67
|
| Net PPE Purchase And Sale |
|
0.00
+100.00%
|
-0.01
+94.26%
|
-0.16
-313.74%
|
-0.04
|
| Purchase Of PPE |
|
0.00
+100.00%
|
-0.01
+94.26%
|
-0.16
-313.74%
|
-0.04
|
| Sale Of PPE |
|
—
|
—
|
—
|
—
|
| Capital Expenditure |
|
—
|
-0.01
+94.26%
|
-0.16
-313.74%
|
-0.04
|
| Net Investment Purchase And Sale |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Purchase Of Investment |
|
-0.04
-0.45%
|
-0.04
+0.44%
|
-0.04
|
0.00
|
| Sale Of Investment |
|
0.04
+0.45%
|
0.04
-0.44%
|
0.04
|
0.00
|
| Net Business Purchase And Sale |
|
—
|
0.00
+100.00%
|
-0.50
-139.36%
|
-0.21
|
| Purchase Of Business |
|
—
|
0.00
+100.00%
|
-0.50
-66.41%
|
-0.30
|
| Net Other Investing Changes |
|
—
|
—
|
—
|
-0.42
|
| Financing Cash Flow |
|
12.27
+163.66%
|
4.65
-56.42%
|
10.68
-29.13%
|
15.07
|
| Cash Flow From Continuing Financing Activities |
|
12.27
+163.66%
|
4.65
-56.42%
|
10.68
-29.13%
|
15.07
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
0.00
+100.00%
|
-0.29
|
| Repayment Of Debt |
|
—
|
—
|
0.00
+100.00%
|
-0.29
|
| Long Term Debt Payments |
|
—
|
—
|
0.00
+100.00%
|
-0.29
|
| Net Long Term Debt Issuance |
|
—
|
—
|
0.00
+100.00%
|
-0.29
|
| Net Common Stock Issuance |
|
8.13
+55.87%
|
5.22
-51.16%
|
10.68
-37.71%
|
17.15
|
| Proceeds From Stock Option Exercised |
|
5.02
+2871266.29%
|
0.00
-72.91%
|
0.00
|
—
|
| Net Other Financing Charges |
|
-0.88
-57.25%
|
-0.56
+57.41%
|
-1.32
+26.05%
|
-1.78
|
| Changes In Cash |
|
4.50
+292.42%
|
-2.34
-185.57%
|
2.74
+330.61%
|
-1.19
|
| Effect Of Exchange Rate Changes |
|
—
|
—
|
—
|
0.00
|
| Beginning Cash Position |
|
6.57
-26.27%
|
8.91
+44.29%
|
6.18
-16.11%
|
7.36
|
| End Cash Position |
|
11.08
+68.54%
|
6.57
-26.27%
|
8.91
+44.29%
|
6.18
|
| Free Cash Flow |
|
-7.77
-11.03%
|
-7.00
+6.04%
|
-7.45
+52.35%
|
-15.62
|
| Interest Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Income Tax Paid Supplemental Data |
|
0.00
-100.00%
|
0.01
-45.80%
|
0.01
|
0.00
|
| Common Stock Issuance |
|
8.13
+55.87%
|
5.22
-51.16%
|
10.68
-37.71%
|
17.15
|
| Interest Received CFO |
|
—
|
—
|
—
|
—
|
| Issuance Of Capital Stock |
|
8.13
+55.87%
|
5.22
-51.16%
|
10.68
-37.71%
|
17.15
|
| Sale Of Business |
|
—
|
—
|
0.00
-100.00%
|
0.09
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-03 View
- 8-K2026-03-30 View
- 8-K2026-03-23 View
- 8-K2026-03-09 View
- 8-K2026-03-06 View
- 8-K2026-02-12 View
- 10-Q2026-02-11 View
- 42025-12-19 View
- 42025-12-19 View
- 42025-12-19 View
- 42025-12-19 View
- 42025-12-19 View
- 42025-12-19 View
- 42025-12-19 View
- 42025-12-19 View
- 42025-12-19 View
- 8-K2025-12-18 View
- 42025-12-17 View
- 42025-12-17 View
- 42025-12-17 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|